Neogenomics

Q2 FY2026 EarningsQ3 FY26 preliminary revenue of $209M slightly beat the $205.9M consensus, driven by robust 28% YoY growth in Next-Generation Sequencing (NGS). While management maintained full-year revenue and Adjusted EBITDA guidance, they signaled a likely upward revision to the revenue midpoint following the earnings call. The announcement of a leadership succession plan, with Warren Stone stepping in as CEO in Jan 2027, suggests a focus on strategic continuity amid positive top-line momentum.